Polatuzumab Vedotin Approved for Previously Untreated Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, and High-Grade B-Cell Lymphoma

The FDA has approved polatuzumab vedotin-piiq (Polivy®, Genentech, Inc.) plus R-CHP (rituximab, cyclophosphamide, doxorubicin, and prednisone) for adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or high-grade B-cell lymphoma (HGBL); including those who have an International Prognostic Index (IPI) score of 2 or greater. Why it matters: "Although most patients (depending on prognostic factors) can be cured with R-CHOP (rituximab, cyclo...

Continue reading

Copyright © Oncology Data Advisor. All rights reserved.